CYTK Investor Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Cytokinetics, Inc.

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly misleading investors regarding the New Drug Application (NDA) submission timeline for aficamten, which may have resulted in financial losses for shareholders [2]. Group 1: Company Overview - Cytokinetics, Inc. is a biopharmaceutical company focused on developing first-in-class muscle activators and next-in-class muscle inhibitors aimed at treating diseases that compromise muscle performance [1]. Group 2: Allegations and Legal Proceedings - The lawsuit claims that during the class period from December 27, 2023, to May 6, 2025, Cytokinetics made materially false statements about the expected approval timeline for aficamten's NDA, which was anticipated in the second half of 2025 based on a PDUFA date of September 26, 2025 [2]. - The company allegedly failed to disclose significant risks related to its submission of a Risk Evaluation and Mitigation Strategy, which could delay the regulatory process [2]. - Shareholders experienced financial losses when the true situation regarding the NDA submission was revealed [2]. Group 3: Participation in Class Action - Shareholders interested in serving as lead plaintiffs must submit their papers by November 17, 2025, and can choose to remain absent class members if they do not wish to participate [3].